The FDA on June 6 approved a new indication for Merck’s Prevymis (letermovir). It can now be used to prevent cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients. The oral antiviral was first approved in 2017 to prevent CMV in CMV-seropositive recipients of allogenic hematopoietic stem cell transplants. As a preventive agent against CMV, Prevymis currently holds covered or better status for 82% of all insured lives under the pharmacy benefit. About 19% of lives have preferred access to Prevymis.
SOURCE: MMIT Analytics, as of 6/7/23